Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

NuCana’s Pancreatic Cancer Trial Halted Due to Futility

Shares of U.K.-based NuCana were down more than 21 percent after the company announced suspended enrollment of patients in a late-stage pancreatic cancer study.

Read More »

AstraZeneca’s Lynparza gets EU nod as first-line ovarian cancer maintenance treatment

Lynparza was approved as a first-line maintenance treatment for a type of advanced ovarian cancer by the European Commission.

Read More »

Lynparza stalls pancreatic cancer in patients with BRCA mutations: study

AstraZeneca and Merck & Co.’s Lynparza helped patients with advanced pancreatic cancer who carry BRCA gene mutations go nearly twice as long without their disease worsening than those who received a placebo, according to data from a late-stage clinical trial.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!

Subscribe

Ad Right Bottom